Your browser doesn't support javascript.
loading
Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.
Yamamura, Takashi; Weinshenker, Brian; Yeaman, Michael R; De Seze, Jerome; Patti, Francesco; Lobo, Patricia; von Büdingen, H-Christian; Kou, Xiujing; Weber, Kristina; Greenberg, Benjamin.
Afiliación
  • Yamamura T; National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4 Chome-1-1 Ogawahigashicho, Kodaira, Tokyo 187-8551, Japan. Electronic address: yamamura@ncnp.go.jp.
  • Weinshenker B; Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.
  • Yeaman MR; Department of Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095, USA; Division of Molecular Medicine, Harbor-UCLA Medical Center, 1000 W Carson St, Torrance, CA 90509, USA.
  • De Seze J; Hôpital de Hautepierre, 1 Av. Molière, Strasbourg 67200, France.
  • Patti F; AOU Policlinico Vittorio Emanuele, Università di Catania, Catania 95123, Italy.
  • Lobo P; ApotheCom, 6th Floor, Holborn Gate, 26 Southampton Buildings, London WC2A 1AN, UK.
  • von Büdingen HC; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel 4070, Switzerland.
  • Kou X; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel 4070, Switzerland.
  • Weber K; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel 4070, Switzerland.
  • Greenberg B; University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA.
Mult Scler Relat Disord ; 66: 104025, 2022 Oct.
Article en En | MEDLINE | ID: mdl-36007339

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neuromielitis Óptica / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Mult Scler Relat Disord Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neuromielitis Óptica / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Mult Scler Relat Disord Año: 2022 Tipo del documento: Article